Resection of Sweat Glands — Surgical Treatment for Hyperhidrosis — Cost, Top Hospitals & Success Rates | MyMedicPlus

Hyperhidrosis is a chronic condition characterised by sweating in excess of that required for thermoregulation. It affects approximately 2.8–5% of the global population and significantly impairs occupational performance, social interaction, and quality of life. The axillae (underarms) are the most commonly affected site for primary focal hyperhidrosis, followed by the palms, soles (plantar), and face/scalp.

Primary hyperhidrosis involves overactivity of the eccrine sweat glands — the predominant secretory gland type, distributed across the entire body surface but concentrated in the axillae, palms, and soles. Apocrine glands, found principally in the axillae and groin, contribute to body odour (osmidrosis) rather than high-volume sweating. Surgical resection procedures principally target eccrine gland destruction or removal in the axillary region, although the anatomy means apocrine glands are concurrently addressed.

The Hyperhidrosis Disease Severity Scale (HDSS) is the primary validated instrument for grading severity: a score of 3 ("sweating is barely tolerable and sometimes interferes with daily activities") or 4 ("sweating is intolerable and always interferes with daily activities") defines severe primary hyperhidrosis and is the accepted threshold for advancing to procedural or surgical management after conservative therapies have failed.

The treatment ladder for axillary hyperhidrosis progresses from: topical aluminium chlorhexahydrate antiperspirants (20–25%) → iontophoresis → botulinum toxin injection → energy-based procedures (MiraDry) → surgical resection (curettage, liposuction-assisted curettage) → endoscopic thoracic sympathectomy (ETS) as a last resort. Each step upwards carries greater efficacy alongside greater invasiveness and risk.

Surgical and procedural interventions targeting sweat glands are specifically indicated for the following presentations:

• Severe primary axillary hyperhidrosis (HDSS 3–4): The principal indication for gland resection or MiraDry treatment. Defined as functionally impairing, bilateral, symmetrical axillary sweating without an identifiable secondary cause, present since adolescence, and unresponsive to first- and second-line treatments.
• Palmar hyperhidrosis: Excessive sweating of the palms that interferes with handwriting, instrument playing, computer use, or professional activities. Palmar hyperhidrosis is not amenable to local surgical resection (sweat glands are distributed across the entire palm). Botulinum toxin injections (using palmar blocks or ice anaesthesia) and iontophoresis are the procedural mainstays; endoscopic thoracic sympathectomy at the T2 level is the surgical option, with the significant caveat of compensatory hyperhidrosis risk.
• Plantar hyperhidrosis: Plantar (sole) sweating frequently coexists with palmar hyperhidrosis. Iontophoresis (direct current devices with water trays) and botulinum toxin are first-line procedural treatments. Lumbar sympathectomy for plantar hyperhidrosis carries high compensatory sweating risk and is rarely performed.
• Axillary osmidrosis: Excessive body odour arising from apocrine gland overactivity. Shares anatomical distribution with axillary hyperhidrosis; surgical resection of the axillary skin and subcutaneous tissue — which contains both eccrine and apocrine glands — addresses both hyperhidrosis and osmidrosis simultaneously.
• Secondary hyperhidrosis: Sweating secondary to systemic causes (menopause, lymphoma, tuberculosis, hyperthyroidism, phaeochromocytoma, medications) must be excluded before any surgical intervention. Surgical sweat gland resection is not appropriate for secondary hyperhidrosis, as the root cause requires systemic treatment.

Before advancing to procedural or surgical management, patients should have completed a structured step-wise trial of less invasive therapies and meet specific eligibility criteria:

• Failed conservative therapies: Documented trial of aluminium chlorhexahydrate antiperspirant (20–25%), applied nightly for a minimum of 4 weeks, before procedural treatment is considered. Iontophoresis (for palmar/plantar hyperhidrosis) should also have been trialled with a minimum of 6–10 sessions.
• HDSS score 3 or 4: Surgical and procedural interventions are validated for severe primary hyperhidrosis (HDSS 3–4) where sweating interferes with daily activities despite conservative management.
• Age: Primary hyperhidrosis typically presents in adolescence. Surgical intervention is generally deferred until the patient is physiologically and psychologically mature (17–18 years for most procedures). MiraDry has FDA clearance for use in patients aged 17 and above.
• Secondary cause exclusion: A structured secondary screen — including thyroid function tests, fasting blood glucose, full blood count, and age-appropriate cancer screen — must exclude systemic causes before labelling hyperhidrosis as primary.
• BMI and anatomy: Obese patients with deep axillary fat may have a higher recurrence rate after curettage due to incomplete access; liposuction-assisted curettage (LAC) addresses this through improved visualisation.
• Realistic expectations and informed consent: Patients must be counselled on the expected efficacy, recovery, recurrence risk, and the specific risk of compensatory hyperhidrosis for ETS procedures before consenting.

A range of surgical and non-surgical procedural options address hyperhidrosis at different levels of invasiveness:

• MiraDry microwave thermolysis (FDA-cleared): A non-invasive device delivering controlled microwave energy (5.8 GHz) to the axillary dermis-subcutaneous junction where sweat glands are concentrated. The handpiece simultaneously cools the epidermis while heating the target zone to 55–65 °C. The pivotal GLOW trial (2012) demonstrated an 82% reduction in axillary sweat at 12 months, sustained at 24 months in follow-up studies. One to two sessions achieve durable results. Hair reduction is a common concomitant finding. Considered the preferred non-surgical procedural option for axillary hyperhidrosis.
• Subcutaneous curettage (Shelley-Hurley technique): Performed under local or tumescent anaesthesia via small axillary incisions. A blunt-tipped curette is used to scrape the undersurface of the axillary skin, physically disrupting eccrine and apocrine glands in the subdermal plane. Reported success rates of 70–90% at one year. A key advantage is the preservation of axillary hair follicles and skin surface. The technique was refined by Hurley and Shelley in 1963 and remains clinically relevant.
• Liposuction-assisted curettage (LAC): Combines tumescent liposuction with curettage to improve access to deeper gland clusters, particularly in patients with thicker subcutaneous tissue. Reduces blunt trauma to overlying skin and associated bruising. Studies report comparable efficacy to curettage alone with potentially lower recurrence.
• Open surgical excision (ellipse or en bloc resection): Surgical excision of the axillary skin bearing sweat glands, with primary closure. Offers the highest gland destruction rate but leaves a visible linear scar, restricts shoulder movement during healing, and carries higher wound complication rates. Reserved for cases where curettage has failed or when concurrent osmidrosis management is indicated.
• Endoscopic thoracic sympathectomy (ETS, T2–T4): Minimally invasive division of the thoracic sympathetic chain under general anaesthesia via 2–3 small thoracic incisions. Effective for palmar hyperhidrosis (T2 level) and axillary hyperhidrosis (T3–T4). Critical limitation: compensatory hyperhidrosis — excessive sweating at alternative body sites (trunk, thighs, feet) — occurs in 30–50% of patients and is the primary reason ETS is now reserved as a last-resort option after all other therapies have failed. Gustatory sweating (sweating triggered by eating) occurs in approximately 10–15% of patients post-ETS.

Procedural and surgical management of hyperhidrosis delivers significant, durable benefits:

• Durable efficacy: MiraDry achieves an average 82% reduction in axillary sweating at 12 months with 1–2 sessions, sustained in long-term follow-up. Surgical curettage achieves 70–90% reduction, with some studies reporting durable results at 5 years. ETS eliminates palmar sweating in over 95% of patients, though compensatory sweating must be considered.
• Permanent gland destruction: Unlike botulinum toxin (which wears off in 6–12 months), both MiraDry and surgical curettage physically destroy or remove sweat glands, which do not regenerate. The effect is therefore long-term and avoids the need for repeated expensive injections.
• Quality of life improvement: Validated quality-of-life instruments consistently demonstrate dramatic improvement after successful treatment — patients report freedom to wear light-coloured clothing, confidence in professional and social settings, and relief from the social anxiety associated with visible sweating.
• Concurrent odour reduction: Destruction of apocrine glands alongside eccrine glands in the axillary subdermal plane reduces osmidrosis (body odour) as a secondary benefit, which is particularly valued by patients with concurrent axillary odour concerns.
• Minimal systemic effect: The eccrine glands of the axillae represent only a small fraction of total body sweat gland mass. Destruction of axillary glands does not impair thermoregulation or produce systemic heat intolerance in the vast majority of patients.

Each treatment modality carries a specific complication profile that must be discussed in detail during pre-procedure counselling:

• Compensatory hyperhidrosis (ETS): The most serious and impactful complication of ETS. Occurs in 30–50% of patients and can, in severe cases, be more distressing than the original palmar hyperhidrosis. Sites affected include the trunk, thighs, and groin. Severity is related to the level of sympathetic chain interruption — clipping at T3 rather than T2 reduces risk but also reduces palmar efficacy. Reversal (sympathetic nerve reconstruction) is possible in selected cases but technically demanding and inconsistently effective.
• Haematoma and seroma: Accumulation of blood (haematoma) or serous fluid (seroma) in the subcutaneous space after curettage or open resection. Managed by needle aspiration. Incidence is 5–10% with curettage; compression dressings reduce formation risk.
• Wound infection: Axillary skin flora is diverse; wound infection rates after open resection are 3–8%. Pre-operative skin preparation with chlorhexidine, prophylactic antibiotics, and careful wound closure reduce this risk.
• Skin necrosis: Over-aggressive curettage can devascularise the overlying skin flap, leading to partial-thickness skin loss. Experienced surgical technique — maintaining at least 3–4 mm of dermal thickness — is the key safeguard.
• Sensation and hair changes: Transient or permanent loss of axillary hair is an expected outcome of MiraDry and curettage. Altered sensation (numbness, hypersensitivity) in the axillary region may persist for several weeks before resolving.
• MiraDry-specific effects: Temporary swelling, bruising, and altered sensation in the axilla lasting 1–2 weeks are common and expected. Brachial plexus injury is an extremely rare but reported complication, making proper patient positioning and depth control critical.
• Incomplete treatment and recurrence: Approximately 10–30% of patients treated with curettage experience partial recurrence of sweating after 12–24 months as residual glands recover function. Repeat treatment is possible.

Recovery and follow-up protocols differ by treatment modality:

• MiraDry aftercare: Significant axillary swelling, bruising, and tenderness are normal for the first 1–2 weeks. Ice packs and oral NSAIDs (ibuprofen 400 mg three times daily) manage discomfort. Patients are advised to wear loose-fitting, breathable clothing and to avoid axillary deodorants containing aluminium for one week. Light activities can resume within 24–48 hours; strenuous upper-body exercise is deferred for 2–3 weeks. Final results are assessed at 3 months.
• Curettage and LAC aftercare: Compression dressings are worn for 1–2 weeks to reduce seroma risk and support skin adherence. Drainage tubes (if used) are removed at 24–48 hours. Patients can typically return to office work within 5–7 days; heavy lifting and repetitive shoulder use are restricted for 3–4 weeks. Scar management (silicone strips, massage) may be initiated after suture removal at 10–14 days.
• ETS aftercare: Hospital admission of 1–2 days for monitoring of pneumothorax (collapsed lung — an uncommon but recognised intraoperative risk). Post-operative chest X-ray confirms lung re-expansion. Shoulder movement is typically near-normal within 1 week. Patients are counselled specifically on compensatory sweating — that it may appear in the weeks following surgery, often becomes less severe over the first 6–12 months, and should be discussed promptly at the first post-operative review.
• Long-term follow-up: Sweat testing (starch-iodine test or gravimetry) at 3 months and 12 months after intervention provides objective documentation of treatment response and guides the decision for further treatment sessions if needed.

Treatment costs vary significantly by modality, provider type, and geographic location:

• Botulinum toxin axillary injection (non-surgical, 6–12 months): USD 600–1,500 per bilateral axillary treatment at a specialist dermatology or plastic surgery clinic. 50 units of onabotulinumtoxinA per axilla (100 units total) is the standard evidence-based dose. Must be repeated every 6–12 months, making long-term cumulative cost high (USD 1,200–3,000/year).
• MiraDry: USD 1,500–3,500 per session in the US and Europe; 1–2 sessions recommended. A single MiraDry session, while expensive, provides durable long-term efficacy that compares favourably with the lifetime cost of repeated botulinum toxin treatments.
• Subcutaneous curettage: USD 1,500–4,000 depending on geographic location and whether performed under local or general anaesthesia. A one-time procedure with durable results, making it highly cost-effective over a 5–10 year horizon.
• Endoscopic thoracic sympathectomy (ETS): USD 5,000–15,000 in private hospitals in the US and Western Europe, including anaesthetist fees and one to two nights of hospital admission. Cost is lower in medical tourism destinations (India, Thailand: USD 1,500–4,000).
• Medical tourism savings: MiraDry is available at accredited cosmetic clinics in South Korea, India, and Thailand for USD 700–1,500 per session — representing 50–70% savings. ETS is commonly performed in specialist thoracic surgery centres in India (Mumbai, Chennai) and Thailand for USD 1,500–3,500 inclusive of hospital stay.

Multiple non-surgical options should be exhausted before advancing to procedural sweat gland resection:

• Topical aluminium chloride hexahydrate (20–25%): The primary first-line treatment for mild-to-moderate axillary hyperhidrosis. Applied to dry axillary skin at bedtime and washed off in the morning, 2–3 times weekly. Efficacy is 30–50% reduction in sweating; skin irritation is the main side effect. Available without prescription in many countries.
• Iontophoresis: The evidence-based first-line procedural treatment for palmar and plantar hyperhidrosis. Hands or feet are immersed in shallow water trays through which a mild direct electrical current (15–20 mA) is passed for 20–30 minutes. The current is thought to block eccrine duct function. Requires 6–10 initial sessions over 2–3 weeks followed by maintenance sessions every 1–4 weeks. Home devices (cost: USD 300–700) are available for ongoing self-treatment.
• Botulinum toxin A injection: Intradermal injection of 50–100 units of onabotulinumtoxinA (Botox) per axilla blocks pre-synaptic acetylcholine release at eccrine nerve endings. Effects last 6–12 months in the axillae; 4–6 months in the palms (where sweating recurs sooner). Palmar injections are more painful and typically require nerve blocks or local anaesthesia. This remains the preferred second-line treatment before considering surgery.
• Oral anticholinergic medications: Glycopyrronium bromide (glycopyrrolate), oxybutynin, and propantheline reduce sweating through systemic muscarinic receptor blockade. Efficacy is moderate; side effects (dry mouth, blurred vision, urinary hesitancy, constipation) frequently limit tolerability. Topical glycopyrronium tosylate (Qbrexza cloth) is FDA-cleared for axillary hyperhidrosis with a more favourable systemic side effect profile.
• Psychological and behavioural approaches: Biofeedback, relaxation training, and cognitive-behavioural therapy have limited direct evidence for hyperhidrosis but may reduce the anxiety-triggered component of sweating and improve overall quality-of-life scores, particularly as adjuncts to physical treatments.